Artificial intelligence used to uncover ‘dark matter of the plant kingdom’
Brightseed uses its AI-enabled platform to detect natural bioactives important to human health, also known as ‘nature’s dark matter’
Brightseed, a US-based data company, says the natural bioactives it uncovers at scale with its AI-enabled platform are ‘basically gold that is often hidden in supply chains.’
The company uses its AI platform, Forager, to detect the natural bioactives present in plants with a ‘pharma-grade level of visibility’. Natural bioactives can be defined as small molecules that plants produce in response to their environment that interact with human biology.
So far, Brightseed has mapped 1.5 million plant compounds using its Forager platform and raised $63 million in Series B funding. Speaking on the latest episode of the Vitafoods Insights Sustainability Series podcast, Brightseed co-founder and COO Sofia Elizondo explains how the company’s search for bioactives relates to human health.
‘We know that the natural bioactives are critical for health - the largest and most comprehensive study on the impact of diet and longevity basically says that if you don't have plants in your diet, you're bound for a premature death. And it is one of the easiest things that we can do to change that. So, we know that there's something in the plants that is powerful for longevity,’ Elizondo explains.
‘The pharmaceutical industry knows that it is these small natural compounds that are very powerful. Two thirds of small molecule drugs are derived from them. Aspirin, Metformin for diabetes - there's a lot of value in these small molecules, but the world doesn't know about them. And it's called the "dark matter of the plant kingdom." That's why we built Forager, so that we can see them and then predict what they can do for health.’
Elizondo explains that while agriculture has historically focused on yield, shelf life and the aesthetic of the food produced, little thought has been given to bioactives.
‘We haven't quite optimised for bioactive content. And it turns out that agricultural practices, and the quality of the soil actually have a really important impact on the bioactives and nutrients that plants then can provide us as we eat them,’ she says.
‘So, there is a golden thread here - what is good for the planet is actually pretty good for human health. And it can be really good for business too.’
Brightseed describes its Forager platform as ‘the world’s largest digital platform that illuminates the interaction between plant bioactives and human biology.’ It is the only technology currently capable of predicting what compounds are bioactive and how they impact specific health areas.
Elizondo explains: ‘Forager can see from a single plant, or a single plant sample, thousands of compounds - this is the dark matter. We go from tens to hundreds or even thousands of compounds. Then we can see how each of those compounds connects to potential health benefits. So, we end up with a web and, essentially, a branch of what a single plant tissue can do for health. And not only that, but we can multiply it for all of the plants that we're bringing into the lab.’
‘It's like a Google map of how plants can impact human health,’ she adds.
Brightseed positions its platform as a tool to speed up innovation and de-risk clinical development. The company also has its own IP-protected pipeline of bioactives that positively impact health.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...